Insider Selling: X4 Pharmaceuticals (NASDAQ:XFOR) CFO Sells $36,393.18 in Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO David Kirske sold 8,543 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total value of $36,393.18. Following the completion of the transaction, the chief financial officer owned 167,750 shares in the company, valued at $714,615. This trade represents a 4.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

X4 Pharmaceuticals Price Performance

X4 Pharmaceuticals stock opened at $4.13 on Friday. The stock has a 50 day moving average of $4.08 and a two-hundred day moving average of $3.93. X4 Pharmaceuticals, Inc. has a twelve month low of $1.35 and a twelve month high of $4.83. The stock has a market capitalization of $389.54 million, a price-to-earnings ratio of -0.91 and a beta of 0.35. The company has a current ratio of 10.18, a quick ratio of 9.98 and a debt-to-equity ratio of 0.45.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. X4 Pharmaceuticals had a negative return on equity of 94.90% and a negative net margin of 1,106.30%.The business had revenue of $2.71 million for the quarter, compared to analyst estimates of $3.20 million. As a group, research analysts expect that X4 Pharmaceuticals, Inc. will post -0.77 earnings per share for the current year.

Institutional Investors Weigh In On X4 Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers raised its position in X4 Pharmaceuticals by 5.4% during the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after acquiring an additional 9,690 shares during the last quarter. Indivisible Partners acquired a new stake in shares of X4 Pharmaceuticals in the fourth quarter valued at approximately $40,000. SummitTX Capital L.P. purchased a new position in shares of X4 Pharmaceuticals during the 1st quarter worth approximately $46,000. Squarepoint Ops LLC purchased a new position in shares of X4 Pharmaceuticals during the 4th quarter worth approximately $50,000. Finally, Two Sigma Investments LP acquired a new position in shares of X4 Pharmaceuticals during the 3rd quarter worth approximately $47,000. 72.03% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Weiss Ratings upgraded shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 23rd. Guggenheim initiated coverage on shares of X4 Pharmaceuticals in a report on Monday, March 9th. They issued a “buy” rating and a $12.00 target price on the stock. Wall Street Zen upgraded shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, Leerink Partners started coverage on shares of X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $9.38.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.